Zealand Pharma A/S (OCSE:ZEAL) EV-to-EBIT : -54.41 (As of Apr. 29, 2024)

View and export this data going back to 2010. Start your Free Trial

What is Zealand Pharma A/S EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Zealand Pharma A/S's Enterprise Value is kr37,218.4 Mil. Zealand Pharma A/S's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was kr-684.0 Mil. Therefore, Zealand Pharma A/S's EV-to-EBIT for today is -54.41.

The historical rank and industry rank for Zealand Pharma A/S's EV-to-EBIT or its related term are showing as below:

OCSE:ZEAL' s EV-to-EBIT Range Over the Past 10 Years
Min: -60.64 Med: -12.19 Max: 8.02
Current: -54.41

During the past 13 years, the highest EV-to-EBIT of Zealand Pharma A/S was 8.02. The lowest was -60.64. And the median was -12.19.

OCSE:ZEAL's EV-to-EBIT is ranked worse than
100% of 443 companies
in the Biotechnology industry
Industry Median: 8.4 vs OCSE:ZEAL: -54.41

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Zealand Pharma A/S's Enterprise Value for the quarter that ended in Dec. 2023 was kr20,272.8 Mil. Zealand Pharma A/S's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was kr-684.0 Mil. Zealand Pharma A/S's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -3.37%.

Zealand Pharma A/S EV-to-EBIT Historical Data

The historical data trend for Zealand Pharma A/S's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zealand Pharma A/S EV-to-EBIT Chart

Zealand Pharma A/S Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

Get a 7-Day Free Trial

-12.62

-11.41

-7.46

-10.52

-29.64

Zealand Pharma A/S Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-EBIT	Get a 7-Day Free Trial															-10.52	-10.40	-13.46	-22.65	-29.64

Competitive Comparison of Zealand Pharma A/S's EV-to-EBIT

For the Biotechnology subindustry, Zealand Pharma A/S's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zealand Pharma A/S's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zealand Pharma A/S's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Zealand Pharma A/S's EV-to-EBIT falls into.

Zealand Pharma A/S EV-to-EBIT Calculation

Zealand Pharma A/S's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	37218.380	/	-684.012
	=	-54.41

Zealand Pharma A/S's current Enterprise Value is kr37,218.4 Mil.
Zealand Pharma A/S's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-684.0 Mil.

Zealand Pharma A/S (OCSE:ZEAL) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Zealand Pharma A/S's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 )	=	EBIT	/	Enterprise Value (Q: Dec. 2023 )
	=	-684.012	/	20272.8426
	=	-3.37 %

Zealand Pharma A/S's Enterprise Value for the quarter that ended in Dec. 2023 was kr20,272.8 Mil.
Zealand Pharma A/S's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-684.0 Mil.

Zealand Pharma A/S EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Zealand Pharma A/S's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Zealand Pharma A/S (OCSE:ZEAL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zealand Pharma A/S (OCSE:ZEAL) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

ZLDPF:USA ZEALc:UK 0NZU:UK 22Z:Germany

Address

Sydmarken 11, Soborg, DNK, DK-2860

Website

https://www.zealandpharma.com

Zealand Pharma A/S is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.